Hans Theodor Eich

TL;DR: A new concept, involved site radiation therapy (ISRT), is introduced as the standard conformal therapy for the scenario, commonly encountered, wherein optimal imaging is not available, and it is more conservative than INRT, accounting for suboptimal information and appropriately designed for safe local disease control.

TL;DR: As Syndecan-1 modulates the cancer stem cell phenotype via regulation of the Wnt and IL-6/STAT3 signaling pathways, it emerges as a promising novel target for therapeutic approaches.

TL;DR: Outcome after RT in PET-CT staged patients appears to be better than in earlier series, particularly in stage I disease, suggesting that the curative potential of RT for truly localized FL has been underestimated.

TL;DR: A systematic overview of IsRT is presented, updating key evidence and highlighting differences in the application of ISRT across the lymphoma clinical spectrum, which in turn influence the distribution of macroscopic and potential subclinical disease.

TL;DR: Survivin is a radiation-inducible protein in Ewing’s sarcoma and its down-regulation sensitizes cells toward irradiation significantly and increases apoptosis more than each single treatment alone.